Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease

Published:2022-03-11 Issue:1 Volume:25 Page:347-355
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Rustgi Vinod K.¹²^ORCID,Duff Steve B.³^ORCID,Elsaid Mohamed I.¹⁴^ORCID

Affiliation:

1. Department of Medicine, Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

2. Center for Liver Diseases and Masses, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

3. Veritas Health Economics Consulting, Inc, Carlsbad, CA, USA

4. Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2026702

Reference52 articles.

1. Nonalcoholic Fatty Liver Disease

2. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

3. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States

4. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

5. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THR-β Agonist for Nonalcoholic Steatohepatitis Treatment: Challenges of a Promising Drug;Journal of Clinical and Translational Hepatology;2024-06-20

2. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05

3. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease;PLOS ONE;2024-03-15

4. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30

5. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis;Clinics and Research in Hepatology and Gastroenterology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3